Life After the IPO: What Does Apellis Have Planned After Raising $170m from Public Investors?
Cedric Francois, president and CEO, discusses his debut performance at JP Morgan in which he laid out the company’s plans for a Phase III trial of APL-2, the promising treatment for geographic atrophy. Francois shared the details of the trial, talked about going public, and shared one of the least recognized – but most important – challenges facing biopharma companies.
Activity